Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: April 15, 2022
Accepted: August 10, 2022
Published online: October 13, 2022

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

Recent reports indicate that patients with aggressive non-Hodgkin lymphomas might benefit if concomitantly receiving statins with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin) and prednisone immunochemotherapy. We retrospectively analyzed a cohort of 130 newly diagnosed diffuse large B-cell lymphomas with unfavorable clinical features treated with first-line rituximab, dose-adjusted etoposide, prednisone, vincristine [Oncovin], cyclophosphamide, hydroxydaunorubicin (R-DA-EPOCH) immunochemotherapy in period 2005–2019. A total of 17/130 (13.1%) patients received statins concomitantly with immunochemotherapy, mostly atorvastatin and in intermediate statin dose intensity. Besides tendency to be associated with older age (p = 0.070), there were no other significant associations of statins use with neither sex, disease stage, R-IPI, or other unfavorable disease features (p > 0.05 for all analyses). Also, no significant differences were present considering feasibility (number of cycles with dose escalation/reduction), toxicity (number of cycles with anemia, thrombocytopenia, neutropenia, febrile neutropenia, and septic complications) nor efficacy (response rates) of R-DA-EPOCH regimen (p > 0.05 for all analyses). Also, statin use had no significant association with neither OS (p = 0.480) nor PFS (p = 0.891). Lack of associations of statin use with relevant clinical outcomes was further corroborated by multivariate analyses.

© 2022 S. Karger AG, Basel

References Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, et al. Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leuk Lymphoma. 2022;63(6):1302–13. Ennishi D, Asai H, Maeda Y, Shinagawa K, Ikeda K, Yokoyama M, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2010 Jun;21(6):1217–21. Brånvall E, Ekberg S, Eloranta S, Wästerlid T, Birmann BM, Smedby KE. Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. Br J Haematol. 2021 Nov;195(4):552–60. Bašić-Kinda S, Radman I, Dujmović D, Ilić I, Kralik M, Dobrenić M, et al. R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience. Ann Hematol. 2021 Jun;100(6):1517–24. Pejsa V, Prka Z, Lucijanic M, Mitrovic Z, Pirsic M, Jaksic O, et al. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J. 2017 Feb 28;58(1):40–8. Lucijanić M, Korunić RH, Sedinić M, Kušec R, Pejša V. Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type. Leuk Lymphoma. 2021 Oct;62(10):2535–8. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr;99(8):2685–93. Lucijanić M. An update to the custom-made MS Excel workbook performing the log-rank test with extended functionality and a new original COVID-19 training data set. Croat Med J. 2021 Oct 31;62(5):531–3. Bachy E, Estell JA, Van de Neste E, Bouabdallah R, Bargay J, Delmer A, et al. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: an exploratory analysis of the PRIMA cohort study. Am J Hematol. 2016 Jun;91(4):410–5. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008 Mar 25;5(3):e64. Article / Publication Details

First-Page Preview

Received: April 15, 2022
Accepted: August 10, 2022
Published online: October 13, 2022

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA